Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The observations are of procedural in nature and will be responded to within the stipulated time
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Developed in consultation with clinicians and patients for an enhanced user experience
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
